Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2018, Trinity Innovation Bioventure Singapore (TIBS) is a licensed biomed venture capital fund based in Singapore. The firm is part of the Trinity Innovation Fund group and is managed by a team experienced in venture capital and biotechnology investments. TIBS focuses on the Asian markets, aiming to drive innovation and value in the biomed sector.
TIBS invests in the biomed sector, particularly in biotechnology and healthcare. The firm emphasizes innovation and value creation, seeking to identify emerging opportunities for new drug development in Asian markets. Investment strategies are tailored to leverage the unique dynamics of the region.
TIBS has invested in various biotech companies, including notable names such as Avadel Pharmaceuticals, Epigenic Therapeutics, and Argo Biopharma. Recent activities include significant financing rounds and partnerships, although specific outcomes for these investments are not detailed.
Yes, TIBS often leads investment rounds in the companies they back, particularly in the biomed sector.
TIBS is open to follow-on investments, especially if the company demonstrates significant progress and potential for growth.
The specific size of TIBS's current fund is not disclosed, but it is part of the larger Trinity Innovation Fund group.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.